Compared with meropenem, cefepime-taniborbactam is superior for microbiologic and clinical cure of complicated urinary tract infection, including acute pyelonephritis. Cefepime-taniborbactam is more ...

Credit: Getty Images. A PDUFA target date of February 22, 2024 has been set for this application. The Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application (NDA) ...

Between January 2001 and December 2002, LACHIS provided 134 courses of long-term home antimicrobial therapy for osteomyelitis. No cases of neutropenia were reported for the 121 courses of ...

Carbapenem-resistant Enterobacterales and multidrug-resistant Pseudomonas aeruginosa are a global threat to antimicrobial resistance and may be causative pathogens in cUTI. Cefepime-taniborbactam ...

Topline Data from Phase 3 clinical trial of cefepime-taniborbactam in patients with complicated urinary tract infections (cUTIs) expected first quarter 2022 BARDA extends cost-sharing contract to ...

Cefepime-taniborbactam has been granted Qualified Infectious Disease Product (QIDP) and Fast Track designation by the U.S. Food and Drug Administration (FDA). In October 2022, BARDA awarded a contract ...

Please provide your email address to receive an email when new articles are posted on . McGovern PC, et al. Abstract 731. Presented at: IDWeek; Oct. 19- 23, 2022. Washington (hybrid meeting). A ...

Review the side-effects of Cefepime as documented in medical literature. The term "side effects" refers to unintended effects that can occur as a result of taking the medication. In majority of the ...

Mortality associated with cefepime (Maxipime) was evaluated in a systematic review and meta-analysis of 57 randomized trials comparing cefepime with another beta-lactam antibiotic; the review was ...

Details concerning the Cefepime combination medication encompass its pricing as well as its availability in various forms, including tablets, capsules, syrups, creams, gels, ointments, liquids, and ...

The frequency of neutropenia in patients receiving long-term cefepime therapy for osteomyelitis compared with that in patients receiving other antimicrobials was studied. A comparative case review was ...